67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma

Clinical trial NCT04023331 · TERMINATED

Trial details

NCT number: NCT04023331
Sponsor: Clarity Pharmaceuticals Ltd
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Neuroblastoma Relapsed Neuroblastoma Refractory Neuroblastoma

Start date: 2020-08-18
Primary completion: 2025-01-24
Enrollment: 21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.